SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis.
Kai Su GreeneMichael J LukeyXueying WangBryant BlankJoseph E DrusoMiao-Chong Joy LinClint A StalneckerChengliang ZhangYashira Negrón AbrilJon W EricksonKristin F WilsonHening LinRobert S WeissRichard A CerionePublished in: Proceedings of the National Academy of Sciences of the United States of America (2019)
The mitochondrial enzyme glutaminase (GLS) is frequently up-regulated during tumorigenesis and is being evaluated as a target for cancer therapy. GLS catalyzes the hydrolysis of glutamine to glutamate, which then supplies diverse metabolic pathways with carbon and/or nitrogen. Here, we report that SIRT5, a mitochondrial NAD+-dependent lysine deacylase, plays a key role in stabilizing GLS. In transformed cells, SIRT5 regulates glutamine metabolism by desuccinylating GLS and thereby protecting it from ubiquitin-mediated degradation. Moreover, we show that SIRT5 is up-regulated during cellular transformation and supports proliferation and tumorigenesis. Elevated SIRT5 expression in human breast tumors correlates with poor patient prognosis. These findings reveal a mechanism for increasing GLS expression in cancer cells and establish a role for SIRT5 in metabolic reprogramming and mammary tumorigenesis.